Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093159 | 0.87 | ALOX5 (0.50) | PTGDR2P2RX1TMPRSS4XDHSLC22A12 | |
| SCHEMBL22115305 | 0.82 | PTGDR2 (0.54) | PTGDR2P2RX1CLK4MAPTMEN1 | |
| SCHEMBL5094107 | 0.81 | ALOX5 (0.62) | P2RX1RXFP1TP53MAPTMEN1 | |
| SCHEMBL4977019 | 0.81 | PIM1 (0.47) | XDHSLC22A12CLK4TP53MAPT | |
| SCHEMBL16574038 | 0.81 | PTGDR2 (0.53) | PTGDR2P2RX1CLK4MAPTMEN1 | |
| SCHEMBL6572418 | 0.81 | ADRA2C (0.50) | XDHSLC22A12CLK4ADRA2CCNR1 | |
| SCHEMBL9469214 | 0.80 | ADRA2C (0.55) | XDHSLC22A12CLK4ADRA2CCNR1 | |
| Hydrochloric Acid SCHEMBL6781702 | 0.79 | ADRA2C (0.49) | XDHSLC22A12CLK4ADRA2CCNR1 | |
| SCHEMBL29588586 | 0.78 | XDH (0.44) | PTGDR2P2RX1XDHSLC22A12CLK4 | |
| SCHEMBL18618148 | 0.78 | XDH (0.44) | PTGDR2P2RX1XDHSLC22A12CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | PTGDR2 4109/4885P2RX1 4698/4885TMPRSS4 1770/4885 |
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | PTGDR2 4109/4885P2RX1 4698/4885TMPRSS4 1770/4885 |
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PTGDR2 438/4885P2RX1 171/4885TMPRSS4 2032/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PTGDR2 438/4885P2RX1 171/4885TMPRSS4 2032/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | PTGDR2 4109/4885P2RX1 4698/4885TMPRSS4 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.